Litigation Details for In Re: Zetia (Ezetimibe) Antitrust Litigation (E.D. Va. 2018)
✉ Email this page to a colleague
In Re: Zetia (Ezetimibe) Antitrust Litigation (E.D. Va. 2018)
Docket | ⤷ Sign Up | Date Filed | 2018-06-15 |
Court | District Court, E.D. Virginia | Date Terminated | |
Cause | 15:1 Antitrust Litigation | Assigned To | Rebecca Beach Smith |
Jury Demand | Plaintiff | Referred To | Douglas E. Miller |
Patents | 7,030,106; 7,612,058 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in In Re: Zetia (Ezetimibe) Antitrust Litigation
Details for In Re: Zetia (Ezetimibe) Antitrust Litigation (E.D. Va. 2018)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2019-06-27 | 315 | as U.S. Patent No. 7,030,106. The ’106 patent was Merck’s first sterol non-absorption patent. It has…azetidinone patents include the ’365 patent, the ’115 patent, the ’966 patent, the RE’721 patent, and the…5. Patents are not bulletproof. 44. Patents are not bulletproof. Patents are routinely…azetidinone patent application – issued as U.S. Patent No. 5,631,365. The ’365 patent was the first-issued…compounds. Two issued as patents (the ’106 patent and the ’058 patent). For shorthand, we refer to | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |